FDA Acting Chief Counsel To Be Masoudi
This article was originally published in The Pink Sheet Daily
Executive Summary
Dan Troy will leave agency Nov. 24 after three years which included major Waxman/Hatch reforms and reconsideration of First Amendment issues. Newly appointed deputy chief counsel Masoudi will succeed Troy until a permanent chief counsel is selected by HHS’ Azar.
You may also be interested in...
FDA Chief Counsel Is Assistant Attorney General Bradshaw
Bradshaw brings extensive high-level government service experience to the position as he permanently replaces former Chief Counsel Troy. Deputy Chief Counsel Masoudi has served in the position on an interim basis since Troy’s departure in November.
FDA Chief Counsel Is Assistant Attorney General Bradshaw
Bradshaw brings extensive high-level government service experience to the position as he permanently replaces former Chief Counsel Troy. Deputy Chief Counsel Masoudi has served in the position on an interim basis since Troy’s departure in November.
Teva Legal Challenge Against "Authorized" Generics Rejected By D.C. Court
Any reduction in the economic value of an ANDA first-filer's product during the 180-day exclusivity period "does not rise to the level of absurdity" requiring the court to look beyond the "plain language" of the FD&C Act, D.C. Judge Walton rules. Teva is appealing the decision.